Table 2

Cost effectiveness analysis based on reported data (primary analysis), and sensitivity analysis based on a worst case scenario considering the maximum predicted number of incorrect diagnoses

Primary analysisSensitivity analysis*
Values are mean (95% confidence interval or uncertainty interval) per 100 000 births.
*Excludes 33 cases of possible incorrect diagnoses, including five predicted cases of haemorrhagic stroke/arteriovenous malformation, and an estimated 28 cases with normal prothrombin values in whom prior administration of vitamin K could not be established with certainty (see text).
†Currency conversion rates (26 March 2004): US$1.00 = £0.55, €0.82. Incidence116 (102 to 132)100 (87 to 115) Deaths11 (7 to 14)9 (6 to 13) Years of life lost340 (220 to 470)290 (200 to 410) Life long disability53 (41 to 66)45 (35 to 57) Years lived with disability820 (630 to 1000)700 (540 to 890) Cost of prophylaxis (US$)†100000 (76000 to 124000)100000 (76000 to 124000)
Cost effectiveness ratio (US\$)†87 (60 to 120)100 (69 to 140)